Journal of Pharmaceutical Research International
https://journaljpri.com/index.php/JPRI
<p style="text-align: justify;"><strong>Journal of Pharmaceutical Research International (ISSN: 2456-9119)</strong> is dedicated to publish high quality papers (<a href="https://journaljpri.com/index.php/JPRI/general-guideline-for-authors">Click here for Types of paper</a>) in all areas of pharmaceutical Science including pharmaceutical drugs, community pharmacy, hospital pharmacy, clinical pharmacy, compounding pharmacy, consultant pharmacy, internet pharmacy, veterinary pharmacy, nuclear pharmacy, military pharmacy, pharmacy informatics, pharmaceutics, medicinal chemistry, pharmacognosy, pharmacotherapy, pharmacodynamics, pharmacokinetics, clinical pharmacology, neuropharmacology, psychopharmacology, pharmacogenetics, pharmacogenomics, pharmacoepidemiology, toxicology, theoretical pharmacology, posology, pharmacognosy, behavioral pharmacology, environmental pharmacology, medicine development and safety testing, drug legislation and safety, pharmaceutical microbiology, pharmaceutical molecular biology, pharmaceutical biotechnology. By not excluding papers based on novelty, this journal facilitates the research and wishes to publish papers as long as they are technically correct and scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled, OPEN peer-reviewed, open-access INTERNATIONAL journal.</p> <p style="text-align: justify;">We are happy to announce that we are now a signatory and a proud member of <a href="https://journaljpri.com/index.php/JPRI/sdg-publishers-compact"><strong>SDG Publishers Compact</strong></a>, an initiative by the United Nations.</p>Journal of Pharmaceutical Research Internationalen-USJournal of Pharmaceutical Research International2456-9119Randomized, Single Blind, Standard Controlled, Equivalence Clinical Trial to Evaluate the Comparative Efficacy of Eladi Kasaya Versus Tranexamic Acid Tablet in the Management of Asrigdara (Heavy Menstrual Bleeding): A Clinical Trial Protocol
https://journaljpri.com/index.php/JPRI/article/view/7502
<p><strong>Introduction:</strong> Excessive menstrual bleeding is a common problem in reproductive age group females, and it is reported that 1 in 20 lifetime chances, a female needs consulting the physician for excessive and prolonged menstrual bleeding. Ayurvedic literature describes excessive menstrual bleeding as Asrigdara (HMB). Eladi kasaya is one of the treatment modalities for heavy menstrual bleeding given in classics and hence chosen for the current clinical trial.</p> <p><strong>Methods:</strong> We planned a prospective, randomized, controlled, and equivalence trial on the patients with Heavy menstrual bleeding (blood loss > 80 ml) for the last two cycles or more. Eladi Kasaya 50 ml with honey and sharkara(sugar) thrice a day will be given from day 1 to day 7 for 3 consecutive menstrual cycles to Group A and Tablet Tranexamic acid 500mg thrice a day to Group B. Primary outcome measures are menstrual blood loss improvement, reduction in pain assessed by visual analog scale, and change in Haemoglobin concentration. The secondary outcome measure is improvement in quality of life. All adverse drug reactions will be monitored and reported to Ayush Suraksha, pharmacovigilance center, Maharashtra. Following sample size calculation 46 patients will be recruited in each group to demonstrate equivalence with 80% power. The duration of study will be 2 years. The study is approved through Institutional Ethics Committee dated 07/10/2022, MGACHRC/IEC/Oct-2022/585. Participant recruitment shall be started after getting registered with the Clinical Trial Registry of India.</p> <p><strong>Results: </strong>Current manuscript is a clinical protocol, hence results are yet to derive from the study. Results will be presented in conferences and shall be attempted to publish in indexed/peer-reviewed medical journals.</p> <p><strong>Conclusion: </strong>Conclusion shall be drawn after completion of the clinical study.</p>Trapti AgrawalSaunitra Inamdar Hemanta Kumar Panigrahi Pratiksha Rathod
Copyright (c) 2024 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2024-03-132024-03-133631910.9734/jpri/2024/v36i37502Over-Expression of EFNA2 in Lung Adenocarcinoma: EFNA2 Gene Expression Correlates with Shortened Survival
https://journaljpri.com/index.php/JPRI/article/view/7503
<p><strong>Background:</strong> The incidence of lung adenocarcinoma (LUAD) is increasing worldwide with different prognosis. Ephrin-A2(EFNA2), a member of the Eph/ephrin family, is associated with tumor progression. However, the correlations of EFNA2 with prognosis in LUAD remain unclear. The purpose of this article is to analyze the impact of EFNA2 on the prognosis of LUAD patients through TCGA, Oncomine, and GEPIA databases, and to explore its possible mechanisms.</p> <p><strong>Methods:</strong> This article found a significant correlation between EFNA2 and shortened survival in LUAD patients through TCGA, Oncomine, and GEPIA database analysis. Therefore, we further invested the relationship between the expression and prognostic value of the EFNA2 gene in LUAD</p> <p>patients. Sequential data filtering (survival analysis, independent prognostic analysis, and clinicalcorrelation analysis) was performed. EFNA2 expression was analyzed by the Oncomine database and Tumor Immune Estimation Resource (TIMER). We evaluated the influence of EFNA2 on clinical prognosis using Kaplan-Meier plotter, the PrognoScan database and Gene Expression Profiling Interactive Analysis (GEPIA). The correlation between EFNA2 and cancer immune infiltrates was investigated by TIMER. In addition, correlations between EFNA2 expression and gene marker sets of immune infiltrates were analyzed by TIMER and GEPIA. In addition, gene enrichment analysis was performed by Metascape. Finally, a co-expression analysis was performed by the Oncomine database.</p> <p><strong>Results:</strong> A cohort of LUAD patients showed that high EFNA2 expression was associated with poorer overall survival (OS), disease-free survival (DFS) by TCGA, and EFNA2 was significantly associated with stage in LUAD. In addition, EFNA2 expression was positively correlated with infiltrating levels of B cells and CD8+ T cells. Moreover, the differential expression of EFNA2 was significantly higher in lung adenocarcinoma compared with that in normal controls. Specifically, EFNA2 was positively associated with ADAMTSL5, REEP6, PCSK4, C19orf25, and ANAPC2.</p> <p><strong>Conclusions:</strong> Our data indicate that EFNA2 is a potential diagnostic and prognostic biomarker and a promising molecular therapeutic target to attenuate LUAD progression.</p>Chunmei Liu Yanjiao Wu Huandi ZhouXiaohui GeXiaojing Chang Guohui Wang Xiaoying Xue
Copyright (c) 2024 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2024-03-182024-03-18363102310.9734/jpri/2024/v36i37503